证券日报网讯1月29日，宣泰医药发布公告称，公司预计2025年年度实现归属于母公司所有者的净利润 4507.00万元至5408.00万元，与上年同期相比，将减少7362.06万元至8263.06万元，同比下降57.65%至 64.71%。预计2025年年度实现营业收入39383.00万元至47260.00万元，与上年同期相比，将减少3901.93 万元至11778.93万元，同比下降7.63%至23.02%。 ...

证券日报网讯1月29日，常山药业（300255）发布公告称，公司预计2025年度归属于上市公司股东的净 利润为-28，500万元至-19，000万元，上年同期为-24，947.77万元。 ...

Group 1 - The company and its management are focused on the secondary market stock prices and highly value shareholder interests [1] - The company is dedicated to the development of its core business, enhancing its core competitiveness [1] - The company aims for high-quality development, continuously creating value and returning benefits to shareholders and society [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456) emphasizes that its stock performance is influenced by multiple factors including market conditions and sector rotation, while the company remains focused on its core business development and enhancing its competitive edge [1] Group 1 - The company will continue to enhance its core competitiveness through standardized operations and transparent communication with the market [1] - Jiuzhou Pharmaceutical aims to convey long-term investment value to the market [1]

Core Viewpoint - Erkang Pharmaceutical (300267.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of the listed company between 325 million and 385 million yuan, with a net loss of 332 million to 392 million yuan after deducting non-recurring gains and losses [1] Financial Performance - The company anticipates a net loss of 325 million to 385 million yuan for 2025 [1] - The expected net loss after excluding non-recurring items is projected to be between 332 million and 392 million yuan [1]

Core Viewpoint - Yuan Dong Biotech (688513) has announced the initiation of Phase I clinical trials for its innovative chemical drug EP-0226, aimed at treating neuropathic pain, in collaboration with the Shanghai Institute of Materia Medica and the Zhongke Zhongshan Drug Innovation Research Institute [1] Group 1 - The first subject has been dosed in the clinical trial for EP-0226 [1] - Preclinical studies indicate that EP-0226 demonstrates superior target selectivity, in vivo analgesic activity, and efficacy compared to the approved drug pregabalin [1] - The safety profile of EP-0226 is reported to be good, suggesting it may provide a safe and effective treatment option for patients suffering from neuropathic pain [1]

Core Viewpoint - Xianju Pharmaceutical's wholly-owned subsidiary, Taizhou Xianju Pharmaceutical Co., Ltd., has received the "High-tech Enterprise Certificate" from multiple governmental bodies, marking the renewal of its previous certification [1]. Group 1 - The certificate was issued by the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1]. - This renewal follows the expiration of the previous high-tech enterprise certificate [1].

Core Viewpoint - Harbin Sanlian Pharmaceutical (002900.SZ) has announced its first annual loss since its A-share listing in 2017, with a projected revenue of 790 million yuan for 2025, a decrease of 30% year-on-year, and a net loss estimated between 315 million to 375 million yuan [2][4]. Revenue and Profitability - The company's revenue is expected to drop by 343 million yuan compared to the previous year, primarily due to a significant decline in sales prices and rigid costs [2][4]. - The basic earnings per share are projected to be between -1.19 and -1 yuan [2][4]. - The net profit attributable to shareholders is forecasted to be -375 million yuan, marking a 739.11% decline year-on-year [4]. Price Pressure and Market Competition - A major factor in the company's poor performance is the decline in sales prices, particularly due to the implementation of centralized drug procurement policies, which have severely impacted the prices of core products [3][4]. - The product "Injection of Yanhuning" is facing an average price drop of 86% due to competitive pressures from 31 companies participating in the procurement [5][6]. - The "Ondansetron Hydrochloride Injection" has seen a price reduction of 56.85% after entering the procurement process, leading to a 37.91% decline in revenue despite increased sales volume [8]. Asset Impairment and Expenses - The company has faced significant asset impairments, with a total of 59.49 million yuan in impairment provisions impacting net profit by over 55 million yuan [11][12]. - Inventory write-downs, particularly for "Injection of Yanhuning," have resulted in a reduction of over 87% in recoverable amounts, contributing to the overall financial strain [11][12]. - High fixed expenses have not decreased in line with revenue, leading to increased expense ratios [13]. Strategic Moves and Future Outlook - In response to the challenges, the company is attempting to pivot towards a health-oriented business model, including the establishment of a new division focused on synthetic biology and the launch of new beauty products [14][18]. - However, the beauty industry is highly competitive, and the synthetic biology sector requires significant investment and long development cycles, posing additional challenges for the company [18].

每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 （记者 张明双） 每经AI快讯，润都股份1月29日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损6000 万元~7800万元，同比由盈转亏。国家药品集采政策的持续深入推进，主要制剂产品毛利率同比下降； 国内外市场竞争激烈，部分原料药中间体的产品价格同比进一步下降，原料药中间体合并报表毛利率仍 有降低；对部分非核心产品生产线进行处置。 ...

Group 1 - The company has two innovative drugs, Lai Ruitewei tablets and Angladiwei tablets, that have been approved for market launch [1] - Angladiwei tablets have been included in the 2025 version of the National Medical Insurance Catalog [1] - The Phase III clinical trials for Angladiwei granules for treating uncomplicated influenza A in children aged 2 to 11 and Angladiwei tablets for treating uncomplicated influenza A in adolescents aged 12 to 17 have successfully completed participant enrollment [1]